학술논문
The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk.
Document Type
Academic Journal
Author
Grassmann F; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. felix.grassmann@ki.se.; Institute for Clinical Research and Systems Medicine, Health and Medical University, Potsdam, Germany. felix.grassmann@ki.se.; Mälarstig A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Pfizer Worldwide Research, Development and Medical, Stockholm, Sweden.; Dahl L; Science for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Solna, Sweden.; Bendes A; Science for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Solna, Sweden.; Dale M; Science for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Solna, Sweden.; Thomas CE; Science for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Solna, Sweden.; Gabrielsson M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Hedman ÅK; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Pfizer Worldwide Research, Development and Medical, Stockholm, Sweden.; Eriksson M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Margolin S; Department of Oncology, Södersjukhuset, Stockholm, Sweden.; Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.; Huang TH; Cancer Immunology Discovery, Pfizer Inc., San Diego, CA, USA.; Ulfstedt M; Olink Proteomics, Uppsala Science Park, Uppsala, Sweden.; Forsberg S; Olink Proteomics, Uppsala Science Park, Uppsala, Sweden.; Eriksson P; Olink Proteomics, Uppsala Science Park, Uppsala, Sweden.; Johansson M; Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.; Hall P; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Department of Oncology, Södersjukhuset, Stockholm, Sweden.; Schwenk JM; Science for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Solna, Sweden.; Czene K; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Source
Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Subject
Language
English
Abstract
Objective: Current breast cancer risk prediction scores and algorithms can potentially be further improved by including molecular markers. To this end, we studied the association of circulating plasma proteins using Proximity Extension Assay (PEA) with incident breast cancer risk.
Subjects: In this study, we included 1577 women participating in the prospective KARMA mammographic screening cohort.
Results: In a targeted panel of 164 proteins, we found 8 candidates nominally significantly associated with short-term breast cancer risk (P < 0.05). Similarly, in an exploratory panel consisting of 2204 proteins, 115 were found nominally significantly associated (P < 0.05). However, none of the identified protein levels remained significant after adjustment for multiple testing. This lack of statistically significant findings was not due to limited power, but attributable to the small effect sizes observed even for nominally significant proteins. Similarly, adding plasma protein levels to established risk factors did not improve breast cancer risk prediction accuracy.
Conclusions: Our results indicate that the levels of the studied plasma proteins captured by the PEA method are unlikely to offer additional benefits for risk prediction of short-term overall breast cancer risk but could provide interesting insights into the biological basis of breast cancer in the future.
(© 2023. The Author(s).)
Subjects: In this study, we included 1577 women participating in the prospective KARMA mammographic screening cohort.
Results: In a targeted panel of 164 proteins, we found 8 candidates nominally significantly associated with short-term breast cancer risk (P < 0.05). Similarly, in an exploratory panel consisting of 2204 proteins, 115 were found nominally significantly associated (P < 0.05). However, none of the identified protein levels remained significant after adjustment for multiple testing. This lack of statistically significant findings was not due to limited power, but attributable to the small effect sizes observed even for nominally significant proteins. Similarly, adding plasma protein levels to established risk factors did not improve breast cancer risk prediction accuracy.
Conclusions: Our results indicate that the levels of the studied plasma proteins captured by the PEA method are unlikely to offer additional benefits for risk prediction of short-term overall breast cancer risk but could provide interesting insights into the biological basis of breast cancer in the future.
(© 2023. The Author(s).)